Related Experiment Videos
Spiro and dispiro-1,2,4-trioxolanes as antimalarial peroxides: charting a workable structure-activity relationship
Yuxiang Dong1, Jacques Chollet, Hugues Matile
1College of Pharmacy, University of Nebraska Medical Center, 986025 Nebraska Medical Center, Omaha, Nebraska 68198-6025, USA.
Journal of Medicinal Chemistry
|July 22, 2005
Summary
Researchers discovered novel synthetic 1,2,4-trioxolane antimalarials, identifying a lead compound with a spiroadamantane and spirocyclohexane structure. Despite biopharmaceutical challenges, structure-activity relationships were established for these potential malaria treatments.
Area of Science:
- Medicinal Chemistry
- Organic Synthesis
- Drug Discovery
Background:
- Malaria remains a significant global health challenge, necessitating the development of new antimalarial drugs.
- Existing antimalarials face issues with resistance and toxicity, driving research into novel chemical scaffolds.
Purpose of the Study:
- To discover and characterize novel synthetic 1,2,4-trioxolane compounds as potential antimalarial agents.
- To establish structure-activity relationships (SAR) for 1,2,4-trioxolanes, considering physicochemical, biopharmaceutical, and toxicological properties.
Main Methods:
- Synthesis and screening of 1,2,4-trioxolane derivatives, including achiral dispiro-1,2,4-trioxolane compounds.
- Evaluation of structure-activity relationships by modifying the core structure and assessing antimalarial activity.
- Physicochemical, biopharmaceutical (formulation, administration route, bioavailability), pharmacokinetic, and toxicological profiling of lead compounds.
Main Results:
- An achiral dispiro-1,2,4-trioxolane featuring spiroadamantane and spirocyclohexane moieties was identified as a lead compound.
- Nonperoxidic isosteres and trioxolanes lacking the spiroadamantane group were inactive, highlighting the importance of the specific structure.
- Compounds showed formulation-dependent activity and better efficacy via subcutaneous than oral administration, indicating biopharmaceutical liabilities.
- Increased lipophilicity correlated with improved oral activity despite limited bioavailability.
- High plasma clearance suggested potential metabolic instability for some compounds.
- Toxicological profiles of two compounds were comparable to the established antimalarial artesunate.
Conclusions:
- Synthetic 1,2,4-trioxolanes represent a promising class of antimalarial compounds.
- While exhibiting biopharmaceutical challenges like poor oral bioavailability and potential metabolic instability, SAR studies provide a foundation for optimization.
- The identified lead compound and its analogs warrant further investigation and development as potential new therapies against malaria.